Anri Nishinaka
Overview
Explore the profile of Anri Nishinaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura S, Yamamoto R, Matsuda T, Yasuda H, Nishinaka A, Takahashi K, et al.
Sci Rep
. 2024 Apr;
14(1):9700.
PMID: 38678148
Ocular abnormal angiogenesis and edema are featured in several ocular diseases. S1P signaling via S1P1 likely is part of the negative feedback mechanism necessary to maintain vascular health. In this...
2.
Fuma S, Hidaka Y, Nishinaka A, Yasuda H, Aoshima K, Nakamura S, et al.
Mol Vis
. 2024 Jan;
29:188-196.
PMID: 38222457
Purpose: To investigate the therapeutic effects of eye drops, namely, timolol maleate, a β-adrenergic receptor antagonist, and latanoprost, a prostaglandin F2α analog, on retinal edema in a murine retinal vein...
3.
Tanaka M, Nakamura S, Sakaue T, Yamamoto T, Maekawa M, Nishinaka A, et al.
Arterioscler Thromb Vasc Biol
. 2023 Apr;
43(6):927-942.
PMID: 37078291
Background: Endothelial cell activation is tightly controlled by the balance between VEGF (vascular endothelial cell growth factor) and Notch signaling pathway. VEGF destabilizes blood vessels and promotes neovascularization, which are...
4.
Yoshioka Y, Kobiyama K, Hayashi T, Onishi M, Yanagida Y, Nakagawa T, et al.
Front Immunol
. 2023 Mar;
14:1116238.
PMID: 36891311
Background: Adjuvants are chemical or biological materials that enhance the efficacy of vaccines. A-910823 is a squalene-based emulsion adjuvant used for S-268019-b, a novel vaccine against severe acute respiratory syndrome...
5.
Hidaka Y, Nakamura S, Nishinaka A, Takajo Y, Inamasu S, Yomoda S, et al.
Biol Pharm Bull
. 2023 Mar;
46(3):473-481.
PMID: 36858576
Macular edema causes vision loss in patients with retinal vein occlusion (RVO) and diabetic macular edema (DME). The intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is used for...
6.
Nishinaka A, Tanaka M, Ohara K, Sugaru E, Shishido Y, Sugiura A, et al.
Exp Eye Res
. 2023 Feb;
228:109405.
PMID: 36773739
This study aimed to determine the role of transient receptor potential vanilloid 4 (TRPV4), a calcium (Ca)-permeable cation channel, in the pathophysiology of retinal vascular disease. The retinal vein occlusion...
7.
Nakamura S, Nishinaka A, Hidaka Y, Shimazawa M, Thomas L, Bakker R, et al.
Invest Ophthalmol Vis Sci
. 2022 Jul;
63(8):14.
PMID: 35822950
Purpose: Semaphorin 3A (Sema3A) is a promising therapeutic target for macular edema in age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion (RVO). Anti-vascular endothelial growth factors (anti-VEGFs) are the...
8.
Nishinaka A, Tanaka M, Aoshima K, Kuriyama A, Sasaki T, Otsu W, et al.
FASEB J
. 2022 Apr;
36(6):e22323.
PMID: 35485981
Neovascular glaucoma (NVG) is caused by the formation of new blood vessels in the angle, iris, and cornea in retinal ischemic disease, such as proliferative diabetic retinopathy (PDR) and retinal...
9.
Yasuda H, Tanaka M, Nishinaka A, Nakamura S, Shimazawa M, Hara H
Int J Mol Sci
. 2021 Aug;
22(16).
PMID: 34445595
Neovascular age-related macular degeneration (nAMD) featuring choroidal neovascularization (CNV) is the principal cause of irreversible blindness in elderly people in the world. Integrated stress response (ISR) is one of the...
10.
Yamamoto T, Nitta K, Nishinaka A, Tanaka M, Nakamura S, Shimazawa M, et al.
Exp Eye Res
. 2021 Jan;
204:108453.
PMID: 33503450
Retinal vein occlusion (RVO) is an intractable eye disease that results in reduced visual acuity, associated with retinal ischemia, hemorrhage, and edema. RVO results in excessive ROS production in the...